Form 4: Theravance Biopharma Executive Tax Withholding

Rhonda Farnum, SVP of Theravance Biopharma, reported the withholding of 5,678 shares to satisfy tax obligations related to RSU vesting.

Summary

• Rhonda Farnum, SVP of Commercial & Medical Affairs at Theravance Biopharma, Inc. (TBPH), executed a transaction involving the withholding of 5,678 ordinary shares.
• The transaction occurred on May 20, 2026, at a price of $16.55 per share.
• The withholding was conducted to satisfy tax obligations arising from the vesting of previously granted restricted stock units (RSUs).
• Following this transaction, the reporting person maintains a direct beneficial ownership of 245,771 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event, as it represents a standard tax compliance action rather than a discretionary trade.

Positives

• The transaction was a mandatory tax withholding event rather than an open-market sale, indicating no change in the executive's long-term confidence in the company.

Negatives

• The transaction resulted in a reduction of the executive's total shareholdings by 5,678 shares.

Risks

• None identified; this is a routine administrative tax compliance event.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Management Comments

• The share withholding transaction was with the issuer and did not involve an open market transaction.

Industry Context

StockSavvy.ai notes that routine tax withholding filings are standard corporate governance procedures for executives receiving equity-based compensation and do not typically signal shifts in corporate strategy or market sentiment.

Comparison to Industry Standards

• The filing follows standard SEC reporting requirements for executive equity compensation.
• The use of share withholding to satisfy tax obligations is a common practice among publicly traded biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-market tax withholding event.

Next Steps

• None

Key Dates

Keywords

Theravance Biopharma, TBPH, Insider Trading, Form 4, Tax Withholding, Equity Compensation